Assessment of reproductive hormones and gynaecomastia in male CML patients with imatinib therapy

4^th International Conference and Exhibition on Metabolomics & Systems Biology

April 27-29, 2015 Philadelphia, USA

Veena Singh Ghalaut

Scientific Tracks Abstracts: Metabolomics

Abstract :

It has been observed that decreased testosterone production and gynaecomastia may appear as adverse effects of imatinib therapy but vary sparse work is available in literature. In this study, we prospectively studied testosterone, LH and FSH levels at baseline and at 6 months of imatinib treatment in 34 newly diagnosed male BCR-ABL positive CML patients. While none of the patients had gynaecomastia at 6 months, the proportion of patients with low testosterone levels increased significantly from 11.8% at baseline to 58.8% (p<0.001) and those with high LH and FSH increased significantly from 26.4% and 23.5% to 82.4% and 76.4%, respectively (p<0.001 and p<0.001). Serum testosterone levels decreased significantly (p=0.002) and serum LH and FSH levels increased significantly at 6 months of imatinib therapy (p=0.001 and p=0.003) in comparison to baseline levels. The findings suggest that there may be decreasing effect of imatinib on testosterone levels in adult CML patients but there is need of further supporting studies.

Biography :

Veena Singh Ghalaut did her MBBS from J.N. Medical College Raipur, Madhya Pradesh and M.D Biochemistry from Pt. B.D.S PGIMS Rohtak. She is presently working as Senior Professor and Head in the Department of Biochemistry, Pt. B.D.S PGIMS Rohtak. She has teaching and research experience of approximately 35 years. There are more than 100 national and international publications and few biochemistry books to her credit. She has guided more than 50 MD/MS thesis projects. She is an active member of many associations and has been honored with several awards.